Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1530-1532

  Schupp, Jonas ^a   Becker, Mike ^b   Günther, Jeannine ^b   Müller Quernheim, Joachim ^a   Riemekasten, Gabriela ^b   Prasse, Antje ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CC CHEMOKINE LIGAND 18 PROTEIN; CHEMOKINE; UNCLASSIFIED DRUG; BETA CHEMOKINE;

CAUSE OF DEATH; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE COURSE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG DISEASE; MACROPHAGE FUNCTION; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SYSTEMIC SCLEROSIS; BLOOD; FEMALE; MALE;

CHEMOKINES, CC; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES; MALE; SCLERODERMA, SYSTEMIC;

EID: 84899877462     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00131713     Document Type: Letter

References (10)

1. Tiev KP, Hua-Huy T, Kettaneh A, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011; 38: 1355-1360.
2. Elhaj M, Charles J, Pedroza C, et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013; 40: 1114-1120.
3. Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-2255.
4. Stein M, Keshav S, Stein BM, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. Receptor 1992; 176: 287-292.
5. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
6. Schraufstatter I, Takamori H, Sikora L, et al. Eosinophils and monocytes produce pulmonary and activationregulated chemokine, which activates cultured monocytes/macrophages. Am J Physiol Lung Cell Mol Physiol 2004; 286: L494-L501.
7. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007; 56: 1685-1693.
8. Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006; 173: 781-792.
9. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
10. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.